Avon Q4 Adjusted Operating Income Tops Estimates (AVP)
Beauty products manufacturer and distributor Avon Products, Inc. (AVP



) shares were up early on Tuesday as the company reported a better-than-expected fourth-quarter earnings report; adjusted net income easily topped Wall Street estimates.
The New York-based company reported a loss of $162.2 million, or 37 cents per share, versus a loss of $400,000, or nothing per share, in the year ago period. Adjusting for items such as the write-down for its Silpada business, the company had an operating profit of 37 cents per share.
Revenue for the quarter fell 1% to $2.96 billion from $3 billion a year earlier.
According to analysts polled by Thomson Reuters, the company was expected to earn an adjusted 27 cents per share on revenue of $3 billion.
Avon has be plagued by a dwindling North American market; this continued in the fourth-quarter as revenue in the home market fell 12%. However, the company did show signs of life in the Brazilian and Russian markets, with revenue up 10% and 3%, respectively.
Avon shares were up 67 cents, or +3.88%, during pre-market trading on Tuesday. The stock is down -3.3% over the past year.
The Bottom Line
Shares of Avon Products (AVP



) have a dividend yield of 1.39% based on last night’s closing price of $17.28 and the company’s annualized dividend payout of 24 cents per share.
Avon Products, Inc. (AVP



) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.0 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

FREE Dividend Stock Newsletter
Get the Dividend.com email newsletter to receive:
- A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
- Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
- Tons of great market analysis and recommendations


RSS


Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the
ADVERTISING PARTNERS